American Society of Hirudotherapy

Congestive Heart Failure (Compensated, Investigational Adjunct)

Investigational adjunct in compensated NYHA II heart failure; only small open-label or uncontrolled studies were identified, mostly in Russian-language sources; guideline-directed medical therapy remains primary.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 12, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for heart failure. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for CHF is highly investigational.
What evidence exists?
Only small, low-quality Russian-language studies of leech therapy in chronic heart failure were identified (an open-label study of 110 patients and uncontrolled series); none measured survival or hospitalization. Tier C (highly investigational). Evidence-based therapy per ACC/AHA/HFSA 2022 guidelines (Guideline-Directed Medical Therapy) includes ARNI (sacubitril/valsartan) or ACE inhibitor / ARB, beta-blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor — these reduce all-cause mortality and hospitalization. Many HF patients require anticoagulation or antiplatelet therapy, which contraindicate leech application.
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Worsening anemia in patients with cumulative blood loss across sessions
  • Hypotension or orthostasis, especially on aggressive diuretic regimens
  • Light-headedness, fainting, or fall risk
  • Local skin infection or, rarely, Aeromonas infection
  • Allergic reaction to leech saliva (uncommon)
  • Delay or replacement of GDMT with risk of decompensation, hospitalization, or death
Who should not consider this
  • Patients with NYHA III or IV decompensated heart failure
  • Patients on any anticoagulant therapy (aspirin and clopidogrel, alone or together, are not a contraindication by themselves: tell your doctor, who starts with fewer leeches)
  • Patients within 3 months of MI, unstable angina, or revascularization
  • Patients with symptomatic orthostatic hypotension or recurrent falls
  • Patients with severe valvular disease awaiting surgical intervention
  • Patients with anemia, active infection, or immunosuppression
  • Pregnant patients
What to ask your clinician
  • Am I on full guideline-directed medical therapy (ARNI / ACE-ARB, beta-blocker, MRA, SGLT2 inhibitor)?
  • What is my left-ventricular ejection fraction, NYHA class, and BNP / NT-proBNP trend?
  • Am I a candidate for additional therapies (CRT, ICD, mitral valve repair, transplant, LVAD)?
  • What is my cardiology team's opinion on complementary therapy in my specific case?
  • Will my anticoagulant / antiplatelet status be reviewed before any leech application?
  • What is the practitioner's experience and Aeromonas-prevention plan?
  • How will diuretic dosing and weights be monitored during treatment?
When to seek urgent care
  • Shortness of breath at rest, inability to lie flat, or new orthopnea
  • Weight gain over 2 kg / 4 lbs in 2 days, new or worsening leg swelling
  • Chest pain, pressure, or palpitations (call 911 if severe)
  • Light-headedness, fainting, or a fall
  • Bleeding from a bite site lasting more than 24 to 48 hours
  • Fever above 38.0 C / 100.4 F, spreading redness, or pus
  • Hives, throat tightness, or breathing difficulty

What this does NOT mean

  • This is not FDA-cleared for heart failure.
  • The small open-label and uncontrolled studies that exist do NOT establish efficacy on hospitalization or mortality.
  • Mechanism rationale (preload reduction) does NOT establish clinical benefit equivalent to proven therapies.
  • Leech therapy is NEVER a substitute for full GDMT or device therapy when indicated.
  • Anticoagulation or antiplatelet therapy should NOT be paused for complementary therapy.

Clinical Profile

Category
Cardiovascular
ICD-10
I50.22, I50.32, I50.42, I50.9
Safety tier
High

Evidence Summary

Heart failure management is dictated by ACC/AHA/HFSA guideline-directed medical therapy (ARNI, beta-blocker, MRA, SGLT2 inhibitor). No randomized trial of hirudotherapy for heart failure was identified in PubMed, Europe PMC or ClinicalTrials.gov. The clinical evidence is Russian-language and low in quality: an open-label study of 110 patients with NYHA II-III chronic heart failure allocated by lot to leech therapy (70) or standard care alone (40), reported as a short journal article and a dissertation abstract (Kuznetsova 2008), and uncontrolled series and small comparisons with control groups described in the Baskova and Isakhanyan 2004 monograph (65 patients in the authors' own series; 50 patients, Ustinova 1969; Nazaryan 1999 and 2001; see “What the books describe” below). These reports measured symptoms, six-minute walk distance and laboratory markers, not survival or hospitalization, and use for this indication remains investigational. Critical concerns: many HF patients take anticoagulants (for comorbid atrial fibrillation) or antiplatelets (post-MI), which contraindicate leech application, and aggressive diuresis with orthostasis raises bleeding-tolerance concerns.

What the books describe

Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.

  • Baskova and Isakhanyan count among the indications for hirudotherapy all diseases complicated by circulatory decompensation, and describe their own series of 65 patients with various heart diseases complicated by chronic heart failure; the series did not include patients in the mildest (preclinical) stage or in the stage of irreversible changes in the internal organs[B1].
  • According to their observations, of these 65 patients improvement was noted in 52: in 26 the pain in the right upper abdomen weakened or disappeared, in 25 the enlarged liver became smaller, in 27 shortness of breath lessened, in 14 the daily volume of urine increased; the description of the series has no comparison group[B1].
  • The authors suppose that hirudotherapy is more effective in chronic right ventricular failure and less effective in acute left ventricular failure, but immediately stress that this is only a supposition[B1].
  • By their explanation, the effect in circulatory decompensation is largely determined by the prolonged bleeding from the small wounds: the amount of circulating blood decreases, and the systemic and pulmonary circulations are relieved[B1].
  • As an example they describe a patient with heart failure in whom, after the first session, bleeding from the small wounds continued for more than a day: the heaviness in the right upper abdomen and the shortness of breath lessened, but he refused further treatment because of the loss of a large amount of blood[B1].
  • Among contraindications, Baskova and Isakhanyan name hemophilia, hemorrhagic diatheses, anemias, low blood pressure, acute vascular insufficiency (shock, collapse, fainting) and concurrent use of anticoagulants, and among the complications they describe, a case of severe hemorrhagic diathesis in a patient after hirudotherapy, cited from the work of Shultsev (1958)[B1].
  • Flecken and Michalsen consider the use of anticoagulants an absolute contraindication; aspirin and clopidogrel they do not regard as a ban in themselves, but with them the number of leeches at the first session should be reduced; Michalsen et al. do not write about heart failure in the book[B3].

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Active deep vein thrombosis (acute phase)
  • Critical limb ischemia (ABI <0.4)
  • NYHA III-IV decompensated heart failure
  • Recent MI or unstable angina (<3 months)
  • Symptomatic orthostatic hypotension
  • Severe valvular disease awaiting surgery

Related Conditions

References

  • [B1]

    Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]

    Москва: Монолит(2004)https://search.rsl.ru/ru/record/01007959553

    Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.

  • [B3]

    Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy

    Stuttgart — New York: Thieme(2007)https://books.google.com/books?vid=ISBN9781588905635

    ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.

The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.